home / stock / vyne / vyne news

VYNE News and Press, VYNE Therapeutics Inc Com From 03/19/24

Stock Information
Company Name: VYNE Therapeutics Inc Com
Stock Symbol: VYNE
Market: NASDAQ
Website: vynetherapeutics.com
Menu
VYNE VYNE Quote VYNE Short VYNE News VYNE Articles VYNE Message Board
Get VYNE Alerts

News, Short Squeeze, Breakout and More Instantly...
VYNE - VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inf...
VYNE - VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q...

VYNE - VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceu...

VYNE - VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...
VYNE - Vyne reports positive data from Phase 1b study for vitiligo drug

2024-01-10 18:39:48 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...

VYNE - VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced positive clinical results Program is on track for Phase 2b initiation in Q2 BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEW...

VYNE - VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
VYNE - VYNE Therapeutics says director Lepore buys 13K shares in co

2023-11-20 11:51:49 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics For further details see: VYNE Therapeutics says director Lepore buys 13K shares i...

VYNE - VYNE Therapeutics files to sell 36.27M shares for holders

2023-11-13 17:18:11 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...

VYNE - VYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1M

2023-11-13 08:43:06 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...
Previous 10 Next 10